Related Experiment Videos

Gram-negative bacterial pneumonia in the immunocompromised host

J E Pennington1

  • 1Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.

Seminars in Respiratory Infections
|September 1, 1986
PubMed

Insights

Gram-negative pneumonia is a significant risk for immunosuppressed patients, especially those with neutropenia. Early empiric antibiotic therapy is crucial for managing this serious infection.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Immunology

Background:

  • Gram-negative bacillary pneumonia is a common and serious complication in iatrogenically immunosuppressed patients.
  • Mortality rates correlate directly with the severity of neutropenia.
  • High-risk groups include neutropenic patients, those with prolonged hospital stays, and post-operative individuals like organ transplant recipients.

Purpose of the Study:

  • To review the epidemiology, pathogenesis, diagnosis, and management of Gram-negative bacillary pneumonia in immunocompromised patients.
  • To highlight the importance of infection control and surveillance in preventing Gram-negative pneumonia.

Main Methods:

  • Literature review focusing on Gram-negative pneumonia in immunosuppressed populations.
  • Analysis of pathogenesis, risk factors, diagnostic challenges, and treatment strategies.
  • Evaluation of current recommendations for empiric antibiotic therapy and adjunctive treatments.

Main Results:

  • Airway colonization by Gram-negative bacilli followed by lower respiratory tract infection is the primary pathogenesis.
  • Diagnosis is challenging due to scant sputum production and low blood culture positivity rates.
  • Empiric antibiotic coverage should target common aerobic Gram-negative bacilli, including Pseudomonas aeruginosa, and Staphylococcus aureus.

Conclusions:

  • Prompt empiric antibiotic therapy, typically a beta-lactam and aminoglycoside combination, is essential for suspected bacterial pneumonia in immunocompromised hosts.
  • Infection control measures and surveillance are critical for prevention.
  • Granulocyte transfusions are reserved for refractory cases; immune therapy requires further evaluation.

Related Concept Videos